SHL Medical’s Reunite shortlisted for 2025 innovation awards

SHL Medical is proud to announce that we are a finalist for the PDA Drug Delivery Innovation Award 2025 and the CPHI Pharma Awards 2025 in the Drug Delivery and Device Innovation category.

Presented annually at the PDA Universe of Pre-Filled Syringes and Injection Devices, the PDA Drug Delivery Innovation Award celebrates advancements in injectable drug delivery systems that improve patient care and manufacturing efficiency. Meanwhile, the CPHI Pharma Awards spotlight pharmaceutical and biopharmaceutical excellence across the global supply chain, highlighting breakthroughs in drug delivery and device design, manufacturing technology, and supply chain innovation.

Reunite™, now shortlisted for two global innovation awards, is an easy-to-use, dual-chamber cartridge-based autoinjector featuring SHL Medical’s proprietary Needle Isolation Technology (NIT^®). Designed to support automated reconstitution and delivery of lyophilized formulations, its three-step operation: unlock, twist, and push, helps minimize the challenges and risks associated with manual mixing and dosing.

The dual shortlisting marks an early chapter in Reunite’s journey. As the industry continues to seek safer and more efficient ways to deliver complex biologics, recognition from these two innovation awards demonstrates SHL Medical’s readiness to meet the evolving needs of pharma partners and reinforces our commitment to advancing technology-driven self-injection solutions.

The winners will be announced at PDA Universe 2025 in Vienna and CPHI Frankfurt 2025, where SHL Medical will be exhibiting Reunite and our broader device portfolio.

Meet Reunite

From Vienna to Boston and Frankfurt, SHL Medical will be participating in three major scientific and commercial tradeshows this October.

We look forward to engaging with the pharma community at PDA Universe, PODD, and CPHI Frankfurt to explore how Reunite can be integrated into development pipelines, address the unique requirements of combination products, and open new opportunities for collaboration.